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Type 2 diabetes mellitus (DM) afflicts nearly 16 million persons in the U.S. Forty million
people have impaired glucose tolerance and thus have a 10% annualized risk of developing
type 2 DM. These prevalence rates are estimated to double within the next two decades.
At-risk groups appear to be the elderly and minorities including African, Hispanic and Native
Americans. While the epidemiologic underpinnings for this increase are not fully realized,
there has been a parallel increase in societal obesity, sedentary lifestyle and a marked increase
in type 2 DM among children. Although there have recently been noteworthy advances in the
field of cardiovascular medicine, cardiovascular case fatalities remain the leading cause of
death among diabetic patients. According to national health statistics, there continues to be
a downward trend in cardiovascular mortality and morbidity. This observation has not been
consistently noted among patients with DM and has led many to re-evaluate current
treatment goals and pharmacologic regimens for the at-risk patients with type 2 DM. This
shifting treatment paradigm for diabetic patients has led to a ratcheting down of targeted risk
factor goals including low-density lipoprotein cholesterol, systolic and diastolic blood
pressure, and serum glucose levels with a requisite increase in the number of pharmacologic
agents being administered. This review focuses on the current adjunctive pharmacologic
treatment regimen that is well suited for patients with type 2 DM. (J Am Coll Cardiol
2002;40:652–61) © 2002 by the American College of Cardiology Foundation
One hundred million persons have a history of diabetes
mellitus (DM) worldwide, 15.7 million reside in the U.S.
and conservative estimates suggest that one third of the U.S.
diabetic population remains undiagnosed. Furthermore, an
additional 40 million persons have insulin resistance syn-
drome and thus are at heightened risk for developing type 2
DM (1). These numbers are projected to double in the next
decade primarily among middle-aged adults, the elderly (2)
and, unexpectedly, among children. Although the under-
pinnings of these epidemiologic observations have yet to be
fully realized, there has been a parallel increase in the
prevalence of societal obesity (3). Unfortunately, cardiovas-
cular complications remain the leading cause of death
among patients with type 2 DM accounting for 70% of all
case fatalities. Although there has been a recent decline in
the age-adjusted mortality rate among patients with cardio-
vascular disease, there has not been a coinciding reduction
in the adjusted mortality rates among patients with diabetes
(4,5) (Fig. 1). Further delineating this heightened risk are
data from a Finnish-based population study (6). In this large
series, patients with diabetes and history of myocardial
infarction (MI) had a yearly vascular event rate (including
cardiovascular death, stroke, or MI) of 18.5% which was
twofold greater than their nondiabetic counterparts. In fact,
patients with diabetes and no prior history of MI had an
event rate of 7.3%, while patients with neither a history of
diabetes nor MI had an annual event rate of 1.1%. Similar
data have compelled numerous expert panels, including the
Joint National Committee (JNC VI), American Diabetes
Association (ADA) and the National Cholesterol Educa-
tion Program (NCEP), to recommend an aggressive risk
factor modification program, with a ratcheting down of
traditional risk factors and the early addition of oral anti-
platelet therapy.
HYPERGLYCEMIA
Serum glucose level not only defines the onset of diabetes
(7,8) but also is associated with an increased risk of future
cardiovascular events among diabetic (9) and nondiabetic
patients (10,11) as evidenced by numerous epidemiologic
studies (12). Most recently, data from the European Pro-
spective Investigation of Cancer and Nutrition-Norfolk
suggest that serum glucose level is associated with an
increased risk of death among nondiabetic patients even in
the lower quartiles of HgbA1c (13). In this cohort of4,600
men followed up for four years, there was a graded increase
in the Relative Risk of all-cause mortality based on the
glycated hemoglobin (5%, 1.00; 5% to 5.4%, 1.41; 5.5% to
6.9%, 2.07; 7%, 2.64; p 0.001). Excluding patients with
diabetes and ischemic heart disease, a 1% increase in the
HgbA1c was associated with a relative risk of 1.46 (1.00 to
2.12, p  0.05) for all-cause mortality. Although there are
abundant data linking both fasting glucose and impaired
glucose tolerance to adverse events, the data demonstrating
an improvement in cardiovascular outcomes with an aggres-
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sive glucose lowering treatment strategy have been lacking
among patients with type 2 DM. Although data from UK
Prospective Diabetes Study (UKPDS)-33 clearly demon-
strate a reduction in microvascular complications with
intensive glucose control (14), there was not a concomitant
significant reduction in macrovascular complications, de-
spite a disproportionate 25% risk of suffering a nonfatal MI
or stroke (compared with a 3.4% incidence of developing
blindness or 1% incidence of developing renal failure)
during a 10-year period.
INSULIN RESISTANCE
Insulin resistance precedes the onset of overt hyperglycemia
in approximately 80% of patients (15), is a known cardio-
vascular risk factor, and the definition has recently been
clarified by an expert consensus panel. Although the bio-
logic determinants of insulin resistance are varied and
remain mostly unexplained, there are emerging mechanisms
that have been implicated in the pathophysiology. The
insulin receptor gene is located on chromosome 19 and
there have been no fewer than 50 mutations in this gene
described which, taken in total, cause only rare forms of
insulin resistance. However, insulin resistance appears, in
part, to be genetically determined. Young, nonobese and
glucose-tolerant relatives of patients with type 2 DM have
been shown to be insulin resistant (16,17). In fact, approx-
imately 50% of first-degree relatives are insulin-resistant
many decades prior to the onset of diabetes (18). The
genetic drivers of insulin resistance do not appear to be
absolute, as environmental factors are clearly contributory in
the development of diabetes. The molecular underpinnings
of insulin resistance are not yet defined; nevertheless, there
have been numerous agents implicated that are discussed in
greater detail later in this work.
The recently updated NCEP guidelines recognize insulin
resistance as an important and modifiable cardiovascular risk
factor. Insulin resistance, as determined by this expert panel,
is present when any three of the following exist in a given
patient: a fasting glucose level of 110 mg/dl and 126
mg/dl, elevated triglyceride level 150 mg/dl, central adi-
posity (abdominal girth 40 in. in men and 35 in. in
women), hypertension (130/85 mm Hg) and depressed
high density lipoprotein (HDL) (40 mg/dl in men and
50 mg/dl in women) (Table 1). Insulin resistance has been
linked to increased production of proinflammatory cyto-
kines and ultimately, to the development of both type 2 DM
and atherosclerosis (19–21). In fact, nuclear factor kappa-
beta, a key transcription factor responsible for the expression
of numerous proinflammatory cytokines, is chronically ac-
tivated in the peripheral monocytes of patients with type 2
DM, which is distinctly unique compared with circulating
monocytes among nondiabetic patients (22).
In addition to diet and exercise, modulation of insulin
resistance is currently possible with both metformin and the
thiazolidinediones (TZDs). Although the TZDs were ini-
tially developed for their antioxidant properties, it became
apparent that they had a beneficial effect on serum glucose
levels in insulin-resistant animals (23–26). There are cur-
rently two agents commercially available in the U.S.: ros-
iglitazone and pioglitazone. Troglitazone was voluntarily
withdrawn from the market, in March of 2000, due to
unexpected, severe hepatotoxicity. The TZDs are synthetic
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ADA  American Diabetes Association
ARB  angiotensin receptor blocker
CHD  coronary heart disease
DM  diabetes mellitus
GP  glycoprotein
HDL  high-density lipoprotein
JNC  Joint National Committee
LDL  low-density lipoprotein
MI  myocardial infarction
NCEP  National Cholesterol Education Program
PCI  percutaneous coronary intervention
PPAR  peroxisome proliferation-activated receptor
PTCA  percutaneous transluminal coronary angioplasty
TZD  thiazolidinediones
Figure 1. The survival curves for the depicted disease states are shown.
Data are derived from the National Center for Health Statistics. This
figure was adapted with permission from reference 4.
Table 1. Clinical Correlates of Insulin Resistance (National
Cholesterol Education Program III)
Any Three of the Following
Fasting glucose 110 mg/dl
Triglycerides 150 mg/dl
HDL
Male 40 mg/dl
Female 50 mg/dl
Waist circumference
Male 102 cm
Female 99 cm
Hypertension 130/85 mm Hg
HDL  high density lipoprotein.
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ligands to a family of nuclear receptors named “peroxisome
proliferator-activated receptors” (PPARs). These receptors
are members of the steroid/thyroid hormone receptor super
family of transcription factors and appear to be important in
adipocyte differentiation (27,28). The PPAR family consists
of three distinct receptors: PPAR, PPAR and PPAR.
Once activated, PPAR forms a heterodimer with 9 cis-
retinoic acid receptor, binds to deoxyribonucleic acid regu-
latory regions of target genes, and results in differential gene
expression and protein synthesis. The TZDs’ binding affin-
ity for PPAR appears to correlate with their glucose-
lowering ability. The PPARs are abundantly populated on
adipocytes, intestinal cells and macrophages; however, the
molecular cascade, linking PPAR to adipocyte differenti-
ation and insulin resistance, is yet undefined. However,
there is mounting evidence that adipocyte-derived hor-
mones may play a key role in the development of obesity and
insulin resistance. As these adipocyte-derived hormones
have structure homology to cytokines, they are collectively
referred to as “adipokines” (29). These identified proteins
include tumor necrosis factor-alpha, leptin, adipsin, resistin,
and adiponectin. In particular, resistin has been linked to
the development of insulin resistance in ob/ob and db/db
(inherited obesity and diabetes traits) mouse models (30).
Adiponectin has been linked with insulin sensitivity in
similar diabetic (as well as nondiabetic) mouse models
(31,32). Both of these adipokines appear to be modulated by
the administration of PPAR ligands. If the results of these
preliminary observations are replicated and the molecular
pathways further delineated, modulation of the adipokine
axis may prove to offer a new therapeutic strategy for the
treatment of obesity, insulin resistance, and type 2 DM.
The glucose-lowering effects of TZDs have been studied
extensively in humans. It appears that as a class, they
improve glycemic control somewhat less than the sulfonyl-
urea agents or metformin. On average, the fasting plasma
glucose level is decreased by approximately 45 mg/dl and the
HbA1c by approximately 1% (33,34). The glucose-lowering
effects of these agents appear to plateau at doses 8 mg for
rosiglitazone and 45 mg for pioglitazone.
The TZDs have numerous non–glucose-lowering effects
that are potentially advantageous. They have a favorable
impact on lipoprotein metabolism, fibrinolysis (35), endo-
thelial function, and inflammation. The TZDs may also
have antimitogenic properties (36,37). Patients with type 2
DM have a characteristic lipid profile of elevated triglycer-
ide levels, low HDL levels and modestly elevated low
density lipoprotein (LDL) levels. As a general rule, the
TZD agents increase HDL levels as much as 20% and
decrease triglyceride levels, especially when these levels are
markedly elevated. Although TZD agents minimally elevate
total LDL concentration, they transition small, oxidized
LDL particles to larger buoyant, potentially less atherogenic
particles (38). Troglitazone has also been demonstrated to
result in significant regression of carotid intimal medial wall
thickness (39).
However, TZD use can be associated with potentially
serious side effects. The development of fluid retention and
worsening congestive heart failure symptoms often necessi-
tates the discontinuation of TZD treatment. Thus, these
agents are contraindicated in patients with New York Heart
Association functional class III to IV symptoms. These
agents also can result in significant weight gain. Preclinical
studies in a murine model for familial adenomatous polyp-
osis and sporadic colon carcinoma suggested that activation
of PPAR was tumor producing. Thus, TZDs ought not be
prescribed to persons with familial adenomatous polyposis
coli (40,41).
HYPERTENSION, RENIN-ANGIOTENSIN AXIS, AND DM
Hypertension remains a prevalent and readily modifiable
chronic disease. Fifty million Americans have hypertension
(42), and the incidence of hypertension is notably increased
among patients with dyslipidemia, obesity, and hyperinsu-
linemia (43). It is estimated that 11 million Americans have
both diabetes and hypertension. This “deadly duo” increases
the cardiovascular event rate twofold. Furthermore, hyper-
tension among diabetic patients has been linked with
numerous other vascular complications such as nephropa-
thy, retinopathy, the development of cerebrovascular dis-
ease, and significant decline in cognitive function in middle-
aged diabetic hypertensive patients (44).
Recognizing this link between hypertension and diabetes
to adverse events, numerous expert panels have recom-
mended lower blood pressure targets for patients with
diabetes mellitus (45–47). Prior to substantial efficacy data,
the JNC VI recommended a ratcheting down of the target
blood pressure among diabetic patients to 130/85 mm Hg
(47). The ADA currently recommends a targeted blood
pressure of 130/80 mm Hg. This later recommendation has
now been validated in two large-scale clinical trials. Both
the Hypertension Optimal Treatment (HOT) trial (48) and
UKPDS 38 study (49) implemented a multidrug antihyper-
tension regimen, achieved a targeted low blood pressure,
and demonstrated improved outcomes among the inten-
sively managed diabetic patients. The HOT trial random-
ized 1,501 diabetic patients to a diastolic blood pressure of
90, 85 or 80 mm Hg. Based on the HOT trial findings,
there were an additional 7.4 lives saved per 1,000 patient
years treated in the 80 mm Hg group. Adopting the more
stringent JNC VI guidelines not only seems efficacious but
also likely translates into cost savings with an estimated
lifetime cost savings of $1,450 (50) (Fig. 2).
Numerous pharmacologic agents have been investigated
for the treatment of hypertension among diabetic patients;
however, angiotensin-converting enzyme (ACE) inhibitors
ought to be considered first-line agents among patients with
diabetes. The efficacy was initially established following
acute MI (51) with nephropathy (49,52–55) and in the
presence of CHF. Both the ABCD and Fosinopril versus
Amlodipine Cardiovascular Events randomized Trial
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(FACET) (56) trials randomized type 2 DM patients to
treatment with either an ACE inhibitor or calcium antag-
onist. Both studies demonstrated a reduction in cardiovas-
cular events for patients randomized to ACE inhibition
therapy. The FACET study randomized patients with
diabetes and hypertension to treatment with fosinopril or
amlodipine. Although there was a similar reduction in
diastolic blood pressure among patients taking both agents,
fosinopril treatment was associated with a 50% reduction in
cardiovascular events including acute MI, stroke, or angina
requiring hospitalization. Although not the primary focus of
this trial, these results highlight the importance of ACE
inhibition among diabetic patients. The ACE inhibitors
have also been shown to attenuate the development of
nephropathy and other microvascular complications among
patients with either type 1 or type 2 DM (49).
Further extending the efficacy and indications of ACE
inhibition among patients with diabetes are MICRO-
HOPE data (57). There were 3,577 patients with a reported
history of diabetes enrolled in this trial (58). Patients with a
history of diabetes were eligible for randomization if they
were 55 years and had a history of cardiovascular disease
or one other risk factor for heart disease. There was a 25%
reduction in MI, stroke or cardiovascular death for the
ramipril-treated diabetic cohort (p  0.001) (Fig. 3A). The
mortality rate was 9.7% for the placebo-treated patients
compared to the 6.2% for the ramipril-treated patients (p 
0.001) (Fig. 3B). There was also a significant reduction in
the rate of MI (12.9% vs. 10.2%, p 0.01) and stroke (6.1%
vs. 4.2%, p  0.007) for the ramipril-treated diabetic
patients compared with placebo-treated diabetic patients.
Although angiotensin receptor blockers (ARBs) have
emerged as effective agents in treating hypertension and in
prevention of progression of nephropathy among patients
with type 2 DM, they should be considered for use only
among patients intolerant or allergic to ACE inhibition,
given the current breadth of data for ACE inhibitors. The
ARBs may offer a more comprehensive inhibition of the
Figure 2. This bar graph depicts the lifetime costs associated with the successful implementation of two blood pressure goals. This model was derived using
a 60-year-old diabetic hypertensive patient with no prior history of cardiovascular or end-stage renal disease. This figure was adapted with permission from
reference 50. ESRD  end-stage renal disease; HF  heart failure; MI  myocardial infarction.
Figure 3. The Kaplan-Meier estimates for all-cause mortality for the diabetic patients enrolled in MICRO-HOPE are shown. Figure reproduced with
permission from reference 57.
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renin-angiotensin system via inhibition of the angiotensin II
tissue receptor, a reduced incidence of hyperkalemia, and no
increased incidence of chronic cough associated with long-
term usage (59). The results of four large-scale trials
confirmed earlier pilot studies suggesting beneficial renal
effects of ARBs (Table 2) (60–62). The Reduction of End
points in Noninsulin Dependent Diabetes Mellitus with the
Angiotensin II Antagonist Losartan (RENAAL) and Irbe-
sartan Diabetic Nephropathy Trial (IDNT) trials evaluated
the efficacy of losartan and irbesartan among patients with
type 2 DM with proteinuria and elevated creatinine con-
centration. Both trials demonstrated a significant reduction
in the rate of death, development of end-stage renal disease,
or doubling of the serum creatinine concentration with the
treatment of losartan or irbesartan. The primary composite
end point was 43.5% for the losartan-treated group com-
pared with 47.1% for the placebo-treated group (p 0.024)
in the RENAAL trial. The Irbesartan Microalbuminuria
Type 2 Diabetes Mellitus in Hypertensive Patients (IRMA
II) and Microalbuminuria Reduction with Valsartan
(MARVAL) trials randomized patients with type 2 DM,
microalbuminuria and a normal creatinine concentration to
irbesartan versus placebo, or valsartan versus amlodipine,
respectively. The primary end point in these smaller con-
trolled trials was the development of frank proteinuria. Both
of these trials demonstrated significant reduction in the
development of proteinuria with ARBs. In the MARVAL
trial, 29.9% of valsartan-treated patients returned to normal
albuminuric states compared with 14.5% of the amlodipine-
treated patients (p  0.001). Within the MARVAL trial,
the baseline urinary albumin excretion rate for the valsartan-
treated patients was reduced from 57.97 to 32.3 g/min.
The amlodipine-treated patients’ urinary albumin excretion
rate was minimally affected (55.4 to 50.7 g/min, p 
0.001).
The safety, tolerability and efficacy for beta-blockers
among patients with type 2 DM is now established (63,64).
In a large series of diabetic patients after an acute MI, there
was an approximate 40% reduction in mortality for those
patients receiving beta-blockers (64). The 2-year mortality
rate was 17% for patients being treated with a beta-blocker
compared with 26.6% for those diabetic patients not receiv-
ing a beta-blocker (relative risk, 0.64; 95% confidence
limits, 0.60 to 0.69). Unfortunately, in this large analysis,
only 31% of eligible diabetic patients received treatment
with a beta-blocker following infarction. Efficacy of beta-
blocker therapy is also evidenced in a study of diabetic
patients with known stable coronary artery disease within
the Bezafibrate Infarction Prevention trial (65). Within this
trial, there was a 44% reduction in the three-year mortality
rates for diabetic patients receiving beta-blockers. Treat-
ment with beta-adrenergic antagonists is associated with
insulin resistance and impaired lipid metabolism. Unlike
selective beta-blockers, carvedilol is a nonselective beta
adrenoreceptor and selective alpha adrenoreceptor-blocking
agent. Its ratio of beta to alpha blocking potency is 7.6:1. In
a small prospective randomized controlled trial of patients
with type 2 DM, the efficacy of carvedilol was compared
with atenolol (66). The blood pressure and left ventricular
mass decreased in both treatment groups; however, carve-
dilol use was associated with a significant reduction in
fasting plasma glucose, insulin and triglyceride levels as well
as an increase in HDL cholesterol compared with atenolol.
Carvedilol and atenolol are currently being evaluated in a
large randomized trial.
DYSLIPIDEMIA AND DIABETES
Patients with type 2 DM have a characteristic lipoprotein
profile. These patients have a tendency for hypertriglyceri-
demia, low levels of HDL cholesterol and modestly elevated
LDL cholesterol, with a disproportionate elevated level of
small-oxidized LDL particles. Both the 4S and Cholesterol
And Recurrent Events (CARE) studies have demonstrated
a significant reduction in future cardiovascular end points
for patients with diabetes and coronary heart disease (CHD)
who were with 3-hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitor. A primary prevention strategy is cur-
rently being tested in the Atorvastatin Patients with Non-
Table 2. Clinical Trials Evaluating the Efficacy of Angiotensin Receptor Blockers in Type 2 DM*
N Agents Clinical Setting 1° End Point 2RR p Value
RENAAL 1,513 losartan type 2 DM composite
placebo proteinuria and death 16% 0.024
increased creatinine ESRD or doubling creatinine
94% also HTN
IDNT 1,715 irbesartan HTN death
amlodipine type 2 DM ESRD or doubling creatinine 33%  0.05
placebo proteinuria 900 mg/dl
IRMA II 590 irbesartan type 2 DM UAER
placebo normal creatinine and microalbuminuria 200 g/min and 30% from baseline 70% 0.0004
UAER 20 to 200 g/min
MARVAL 332 valsartan type 2 DM UAER (mean)  0.001
amlodipine microalbuminuria
*Presented at the American Society of Hypertension 16th Annual Scientific Sessions.
DM  diabetes mellitus; ESRD  end-stage renal disease; HTN  hypertension; UAER  urinary albumin excretion rate. See text for trial acronym definitions.
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insulin Dependent Diabetes Mellitus (ASPEN) study and
the Collaborative Atorvastatin Diabetes Study (CARDS).
Additionally, the MRC/BHF Heart Protection Study has
currently enrolled 6,000 patients with diabetes; nearly 4,000
of this group do not have a history of CHD (67). These
trials will undoubtedly shed important light on the efficacy
of utilizing a statin agent for the primary prevention of
CHD among diabetic patients. The recent ATP III and
ADA recommend a multifaceted lipid-lowering regimen
with a targeted LDL of 100 mg/dl and considers diabetes
as a CHD risk equivalent. Table 3 depicts the current ADA
recommendations for the treatment of lipoprotein abnor-
malities among diabetic patients.
ADJUNCTIVE ORAL ANTIPLATELET THERAPY
Numerous plausible biologic mechanisms have been pur-
ported to explain the exceptionally poor outcome of patients
with DM and coronary artery disease. Diabetic patients
have a propensity for adverse arterial remodeling (68,69),
aggressive atherosclerosis (70,71), abnormal endothelial
function (72,73), impaired fibrinolysis, platelet hyperactivity
and a propensity to form neointima following arterial injury.
The diabetic platelet has emerged as a distinct target for
therapeutic intervention. Increased platelet activity is cer-
tainly involved in the increased thrombogenic potential
among diabetic patients. Diabetic platelets are larger, have a
greater number of glycoprotein (GP) IIb/IIIa receptors (74)
and aggregate more readily to known agonists in vitro than
platelets from nondiabetic patients (75). Knobler et al. (76)
measured shear-induced whole-blood platelet adhesion and
aggregation on the extracellular matrix of diabetic and
nondiabetic patients. This ex vivo model more closely
approximates the in vivo environment by maintaining the
presence of other blood elements, shear force and solid
phase subendothelial components. This study demonstrated
increased platelet adhesion and aggregation in diabetic
patients, which loosely correlated with the degree of dyslip-
idemia. Furthermore, a greater percentage of diabetic plate-
lets circulate in an activated state.
It is not surprising that diabetic patients derive substantial
benefit from aspirin therapy. A meta-analysis from the
antiplatelet trialists evaluated the efficacy of aspirin therapy
as a secondary preventive strategy. The diabetic substudy in
this meta-analysis demonstrated a significant reduction in
cardiovascular events for those diabetic patients treated with
aspirin. An estimated 38 vascular events were prevented per
1,000 diabetic patients treated (77). Subgroup analysis from
the U.S. Physicians Health Study evaluated the efficacy of
low-dose aspirin (325 mg, every other day) as a primary
prevention strategy (78). Subgroup analysis of this diabetic
cohort demonstrated a reduction in the MI rate from 10.2%
for the placebo-treated group to 4.0% for the aspirin-treated
group. An aggressive antiplatelet strategy for the primary
prevention of cardiovascular events is also supported by the
Early Treatment Diabetic Retinopathy Study (79). Given
these historical data, aspirin administration is requisite
among diabetic patients with CHD and seems prudent in
patients with type 2 DM at risk for CHD.
Treatment with a thienopyridine may confer additional
benefit among diabetic patients with macrovascular disease.
The Clopidogrel versus Aspirin in Patients at Risk for
Ischemic Events (CAPRIE) trial randomized 19,185 pa-
tients with a history of recent stroke, MI, or peripheral
arterial disease to treatment with either aspirin or clopi-
dogrel. Overall, there was a modest reduction in the
combined event rates of ischemic stroke, MI, or vascular
death associated with clopidogrel treatment compared with
aspirin therapy, 5.83% vs. 5.32% (p  0.043), respectively.
Substudy analysis of the nearly 4,000 diabetic patients from
CAPRIE, randomized to treatment with clopidogrel, dem-
onstrated a significant benefit (80). The annual combined
event rate was 17.7% compared with 15.6% (p  0.042).
ADJUNCTIVE THERAPY DURING
PERCUTANEOUS CORONARY INTERVENTION
Diabetic patients undergoing percutaneous coronary inter-
vention (PCI) have numerous high risk clinical and ana-
tomical characteristics and substantially higher rates of late
MI, late mortality, and restenosis following PCI. Recent
data analyzing over 25,000 patients undergoing PCI suggest
that diabetic patients also have an approximate twofold
increase in in-hospital mortality, following both elective
(1% vs. 2%, p  0.001) and urgent PCI (6.9% vs. 12.7%, p
 0.001). This increased early hazard for death, following
PCI, persisted following multivariable adjustment (odds
ratio 1.4, p  0.04) (81). In addition to aspirin and a
thienopyridine, the adjunctive administration of a GP
Table 3. Order of Priorities for Treatment of Diabetic
Dyslipidemia in Adults
I. LDL cholesterol-lowering
First choice: HMG-CoA reductase inhibitor (statin)
Second choice: Bile acid binding resin (resin) or fenofibrate
II. HDL cholesterol-raising
Behavioral interventions such as weight loss, increased physical
activity, and smoking cessation may be useful
Glycemic control
Difficult except with nicotinic acid, which is relatively
contraindicated, or fibrates
III. Triglyceride-lowering
Glycemic control first priority
Fibric acid derivative (gemfibrozil, fenofibrate)
Statins are moderately effective at high dose in hypertriglyceridemic
subjects who also have high LDL cholesterol levels
IV. Combined hyperlipidemia
First choice: Improved glycemic control plus high dose statin
Second choice: Improved glycemic control plus high dose statin plus
fibric acid derivative (gemfibrozil, fenofibrate)
Third choice: Improved glycemic control plus resin plus fibric acid
derivative (gemfibrozil, fenofibrate)
Improved glycemic control plus statin plus nicotinic acid
(glycemic control must be monitored carefully)
HDL  high density lipoprotein; HMG-CoA  3-hydroxy-3-methylglutaryl-
coenzyme A; LDL  low density lipoprotein.
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IIb/IIIa inhibitor has been associated with an additional
reduction in adverse events following PCI.
The early safety and long-term efficacy of abciximab has
been extensively evaluated among patients with diabetes
undergoing PCI. Of the 2,399 patients randomized within
the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
Trial (EPISTENT), 491 patients had a history of DM and
were randomized to treatment with stent-abciximab, stent-
placebo, or percutaneous transluminal coronary angioplasty
(PTCA)-abciximab (82). The benefit of abciximab therapy
among diabetic patients undergoing PCI was apparent at 30
days, persisted through 1-year follow-up, and remained
significant following multivariate adjustment. At six
months, there was a marked benefit for the stent-abciximab
group compared with the stent-placebo and the PTCA-
abciximab groups for the combined end point of death, MI,
or target vessel revascularization (stent-abciximab, 13.0%;
stent-placebo, 25.2%, p  0.005; PTCA-abciximab,
23.4%). The reduction in this composite was driven by a
reduction in all three end points analyzed. The 6-month
death or MI rate was 6.2% for the stent-abciximab, 12.7%
for the stent-placebo (p  0.041), and 7.8% for the
PTCA-abciximab groups. There was also a significant
reduction in the 6-month target vessel revascularization rate
for the stent-abciximab-treated diabetic patients (stent-
abciximab, 8.1%, stent-placebo, 16.6%, p  0.021, PTCA-
abciximab, 18.4%). Importantly, the efficacy of stent and
abciximab was maintained through one-year follow-up (Fig.
4).
The initial findings from EPISTENT have been further
substantiated by a pooled analysis from EPIC, EPILOG
and EPISTENT (83). The administration of abciximab was
associated with a significant reduction in one-year mortality
among the 1,462 diabetic patients in these trials (4.5% vs.
2.5%, p  0.031). The efficacy of abciximab persisted
among high risk subgroups of diabetic patients including
those with clinical markers of insulin resistance (5.1% vs.
2.3%, p 0.0044), insulin-requiring diabetic patients (8.1%
Figure 4. One-year Kaplan-Meier estimates of the invasive treatment arms for the patients with diabetes mellitus enrolled in Evaluation of Platelet IIb/IIIa
Inhibitor for Stenting Trial (EPISTENT) are shown. A the rate of death or myocardial infarction (MI) within EPISTENT; B the 1-year target vessel
revascularization (TVR) rates. PTCA  percutaneous transluminal coronary angioplasty.
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vs. 4.2%, p  0.073) and those diabetic patients undergoing
multivessel intervention (7.7% vs. 0.9%, p  0.018).
SUMMARY
There remains no doubt that patients with type 2 DM
remain at heightened risk for major cardiovascular events in
the modern era of medical therapy. It is also clear that these
patients derive substantial benefit from current recommen-
dations regarding risk factor modification and available
pharmacologic agents. Unfortunately, attaining the recom-
mended risk factor targets and instituting a broad-based
pharmacologic treatment strategy has been less than suc-
cessful (84). Improving the cardiovascular health among
patients with diabetes will require a ramping up of societal
resources. Focused and effective prevention strategies that
are readily applicable across cultures will be key in order to
delay and ultimately prevent the onset of type 2 DM. The
medical community will need to become engaged with
respect to the unique nature of diabetes mellitus and
vascular disease and implement broad-based treatment
strategies resulting in “poly-pharmacy” of the diabetic per-
son. Lastly, a reinvestment of philanthropy, industry and
government-based research resources will be requisite in
order to propel our current understanding of the diabetic-
vascular axis forward.
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